Figure 1.

Timeline of approval by the FDA of disease-modifying therapies for multiple sclerosis. FDA: Food and Drug Administration; IM: intramuscular; SC: subcutaneous. ^aInterferon beta-1b was also approved in 2009 as Extavia® (which is the Novartis-branded version of the Bayer product Betaseron®). ^bVarious generic versions of glatiramer acetate are in development. Glatopa™ [10] was approved in 2015 by the FDA. Other generic versions were approved in the EU in 2016 and by the FDA in 2017 [11, 12]. ^cBioequivalent generic mitoxantrone was approved in 2006. ^dSubsequently withdrawn (March 2018).